Equfina News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eisai to Launch Parkinson s Disease Treatment Equfina in South Korea
TOKYO, Feb 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai s subsidiary in South Korea, has launched the Parkinson s disease treatment Equfina (safinamide mesilate, safinamide ). This is the first launch of Equfina in the Asian region excluding Japan.
The estimated number of patients with Parkinson s disease is approximately 150,000 in South Korea. Parkinson s disease has high unmet medical needs because of inadequate symptom control using current medications, necessitating new treatment options. This disease is designated as a rare intractable disease in South Korea.
The marketing approval of this drug in South Korea is primarily based on a double-blind, placebo-controlled, Phase III Study (SETTLE study) conducted overseas (including South Korea) to evaluate the efficacy and safety of 24-week oral administration of the once-daily safinamide as an add-on to lev ....

United States , Hong Kong , Republic Of , South Korea , E Ray Dorsey , Japanese Society Of Neurology Parkinson , Newron Pharmaceuticals , Eisai Co Ltd , Public Relations Department , Eisai Korea Inc , Meiji Seika Pharma Co Ltd , Japan Intractable Diseases Information Center , Levodopa Adjunct , Patients With Parkinson Disease , Motor Fluctuations , Randomized Clinical , Global Burden , Disease Study , Japanese Society , Relations Department , ஒன்றுபட்டது மாநிலங்களில் , ஹாங் காங் , குடியரசு ஆஃப் , தெற்கு கொரியா , ஏ ராய் டோர்ஸி , ஜப்பானிய சமூகம் ஆஃப் நரம்பியல் பார்கின்சன் ,